Treatment of Latent Autoimmune Diabetes of the Adult

Completed 64 enrolled Norwegian University of Science and Technology

RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of the study is to clarify whether patients classified as Latent autoimmune diabetes of the adult (LADA) benefit from early treatment with insulin added to per oral treatment and lifestyle measures.

Timeline

Start: 2009-03
Primary completion: 2018-11
Completion: 2018-11

Publications

Results Hals IK, Fiskvik Fleiner H, Reimers N, Astor MC, Filipsson K, Ma Z, Grill V, Bjorklund A. Investigating optimal beta-cell-preserving treatment in latent autoimmune diabetes in adults: Results from a 21-month randomized trial. Diabetes Obes Metab. 2019 Oct;21(10):2219-2227. doi: 10.1111/dom.13797. Epub 2019 Jun 19.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Insulin	Protein / enzyme biologic	0.2 iu/kg	Other
Comparator	Sitagliptin	Small molecule	100 mg	Oral
Comparator	Metformin	Small molecule	1000 mg	—
Comparator	Repaglinide	Small molecule	1 mg	Oral

Treatment of Latent Autoimmune Diabetes of the Adult

Summary

Timeline

Publications

Drugs

Indications